Auro Laboratories [AUROLAB] vs Sun Pharma Advanced [SPARC] Detailed Stock Comparison

Auro Laboratories Limited

BSE
Loading...

Sun Pharma Advanced Research Company Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 19 vital metrics comparison: Auro Laboratories Limited wins in 15 metrics, Sun Pharma Advanced Research Company Ltd. wins in 3 metrics, with 0 ties. Auro Laboratories Limited appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Auro Laboratories Limited Sun Pharma Advanced Research Company Ltd. Better
P/E Ratio (TTM) 48.08 -13.65 Auro Laboratories Limited
Price-to-Book Ratio 3.57 -13.55 Auro Laboratories Limited
Debt-to-Equity Ratio 100.84 -1.21 Auro Laboratories Limited
PEG Ratio 0.01 -11.15 Auro Laboratories Limited
EV/EBITDA 31.14 -22.27 Auro Laboratories Limited
Profit Margin (TTM) 11.39% -53.22% Auro Laboratories Limited
Operating Margin (TTM) 32.83% -700.71% Auro Laboratories Limited
EBITDA Margin (TTM) 32.83% N/A N/A
Return on Equity 4.28% 157.88% Sun Pharma Advanced Research Company Ltd.
Return on Assets (TTM) 1.86% -102.08% Auro Laboratories Limited
Free Cash Flow (TTM) $-180.54M $-3.71B Auro Laboratories Limited
1-Year Return 11.96% 14.56% Sun Pharma Advanced Research Company Ltd.
Price-to-Sales Ratio (TTM) 5.48 87.98 Auro Laboratories Limited
Enterprise Value $2.03B $50.87B Sun Pharma Advanced Research Company Ltd.
EV/Revenue Ratio 7.13 95.73 Auro Laboratories Limited
Gross Profit Margin (TTM) 88.05% -59.53% Auro Laboratories Limited
Revenue per Share (TTM) $46 $2 Auro Laboratories Limited
Earnings per Share (Diluted) $5.20 $-8.25 Auro Laboratories Limited
Beta (Stock Volatility) 0.09 0.19 Auro Laboratories Limited

Auro Laboratories Limited vs Sun Pharma Advanced Research Company Ltd. Stock Performance Analysis

Loading Price Chart...

AUROLAB
SPARC

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Auro Laboratories Limited-1.52%-3.45%6.14%-8.81%2.74%7.86%
Sun Pharma Advanced Research Company Ltd.2.09%-5.81%49.25%68.87%37.58%54.41%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Auro Laboratories Limited11.96%219.81%161.67%1,083.37%3,551.32%4,900.00%
Sun Pharma Advanced Research Company Ltd.14.56%13.10%-5.14%-23.02%148.11%-27.03%

Performance & Financial Health Analysis: Auro Laboratories Limited vs Sun Pharma Advanced Research Company Ltd.

MetricAUROLABSPARC
Market Information
Market Cap i₹1.56B₹46.75B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i4,5572,401,062
90 Day Avg. Volume i4,5432,083,443
Last Close₹262.90₹208.50
52 Week Range₹159.00 - ₹317.00₹108.00 - ₹248.75
% from 52W High-17.07%-16.18%
All-Time High₹317.00 (Feb 18, 2026)₹875.00 (Apr 24, 2006)
% from All-Time High-17.07%-76.17%
Growth Metrics
Quarterly Revenue Growth2.08%-0.43%
Quarterly Earnings Growth37.27%-0.43%
Financial Health
Profit Margin (TTM) i0.11%-0.53%
Operating Margin (TTM) i0.33%-7.01%
Return on Equity (TTM) i0.04%1.58%
Debt to Equity (MRQ) i100.84-1.21
Cash & Liquidity
Book Value per Share (MRQ)₹70.01₹-10.63
Cash per Share (MRQ)₹1.07₹0.03
Operating Cash Flow (TTM) i₹74.16M₹-3,484,287,000
Levered Free Cash Flow (TTM) i₹18.39M₹-3,425,094,000
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Auro Laboratories Limited vs Sun Pharma Advanced Research Company Ltd.

MetricAUROLAB (Apr 26, 2026)SPARC (Apr 22, 2026)
Price Ratios
P/E Ratio (TTM) i48.08-13.65
Forward P/E iN/A2.60
PEG Ratio i0.01-11.15
Price to Sales (TTM) i5.4887.98
Price to Book (MRQ) i3.57-13.55
Market Capitalization
Market Capitalization i₹1.56B₹46.75B
Enterprise Value i₹2.03B₹50.87B
Enterprise Value Metrics
Enterprise to Revenue i7.1395.73
Enterprise to EBITDA i31.14-22.27
Risk & Other Metrics
Beta i0.090.19
Book Value per Share (MRQ) i₹70.01₹-10.63

Financial Statements Comparison: Auro Laboratories Limited vs Sun Pharma Advanced Research Company Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricAUROLAB (2025)SPARC (2025)
Revenue/Sales i191.24M717.66M
Cost of Goods Sold i99.08M1.10B
COGS % of Revenue i51.8%153.2%
Gross Profit i92.16M-381.94M
Gross Margin i48.2%-53.2%
Research & Development iN/AN/A
Operating Income (EBIT) i23.07M-3.34B
Operating Margin i12.1%-465.5%
EBITDA i40.60M-3.23B
EBITDA Margin i21.2%-450.0%
Pre-Tax Income i18.81M-3.43B
Pre-Tax Income % of Revenue i9.8%-477.6%
Income Tax i421,000-2.72M
Income Tax % of Revenue i0.2%-0.4%
Net Income (Profit) i18.39M-3.43B
Profit Margin i9.6%-477.3%

Balance Sheet & Liquidity Metrics

MetricAUROLAB (2025)SPARC (2025)
Cash & Equivalents i3,00019.64M
Total Current Assets i215.14M261.97M
Total Current Assets % of Revenue i112.5%36.5%
Total Current Liabilities i216.42M3.74B
Total Current Liabilities % of Revenue i113.2%521.5%
Long-Term Debt i330.85M1.07B
Long-Term Debt % of Revenue i173.0%149.0%
Total Shareholders Equity i429.68M-2.17B
Retained Earnings i359.52M-23.22B
Retained Earnings % of Revenue i188.0%-3,235.0%
Property, Plant & Equipment i16.55M178.02M

Cash Flow Statement Comparison

MetricAUROLAB (2025)SPARC (2025)
Operating Cash Flow i74.16M-3.48B
Operating Cash Flow % of Revenue i38.8%-485.5%
Capital Expenditures i20,000-97.45M
Free Cash Flow i-180.54M-3.71B
FCF Margin i-94.4%-516.4%
Debt Repayment i0-3.69B
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricAUROLABSPARC
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i6.23M324.52M
Float Shares i2.35M91.32M
% Held by Insiders i60.96%72.96%
% Held by Institutions i0.00%2.56%
% Held by Public i39.04%24.48%

Dividend Analysis & Yield Comparison: Auro Laboratories Limited vs Sun Pharma Advanced Research Company Ltd.

MetricAUROLABSPARC
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A